<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23929771</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-3450</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Society of Nephrology : JASN</Title>
          <ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The pathogenesis of lupus nephritis.</ArticleTitle>
        <Pagination>
          <StartPage>1357</StartPage>
          <EndPage>1366</EndPage>
          <MedlinePgn>1357-66</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.2013010026</ELocationID>
        <Abstract>
          <AbstractText>Lupus nephritis is an immune complex GN that develops as a frequent complication of SLE. The pathogenesis of lupus nephritis involves a variety of pathogenic mechanisms. The extrarenal etiology of systemic lupus is based on multiple combinations of genetic variants that compromise those mechanisms normally assuring immune tolerance to nuclear autoantigens. This loss of tolerance becomes clinically detectable by the presence of antinuclear antibodies. In addition, nucleic acids released from netting or apoptotic neutrophils activate innate and adaptive immunity via viral nucleic acid-specific Toll-like receptors. Therefore, many clinical manifestations of systemic lupus resemble those of viral infection. In lupus, endogenous nuclear particles trigger IFN-α signaling just like viral particles during viral infection. As such, dendritic cells, T helper cells, B cells, and plasma cells all contribute to the aberrant polyclonal autoimmunity. The intrarenal etiology of lupus nephritis involves antibody binding to multiple intrarenal autoantigens rather than the deposition of circulating immune complexes. Tertiary lymphoid tissue formation and local antibody production add to intrarenal complement activation as renal immunopathology progresses. Here we provide an update on the pathogenic mechanisms that lead to lupus nephritis and provide the rationale for the latest and novel treatment strategies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lech</LastName>
            <ForeName>Maciej</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Medical Clinic and Polyclinic IV, University of Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anders</LastName>
            <ForeName>Hans-Joachim</ForeName>
            <Initials>HJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>08</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Am Soc Nephrol</MedlineTA>
        <NlmUniqueID>9013836</NlmUniqueID>
        <ISSNLinking>1046-6673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23929771</ArticleId>
        <ArticleId IdType="pmc">PMC3752952</ArticleId>
        <ArticleId IdType="doi">10.1681/ASN.2013010026</ArticleId>
        <ArticleId IdType="pii">ASN.2013010026</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Liu Z, Davidson A: Taming lupus-a new understanding of pathogenesis is leading to clinical advances.
Nat Med
18: 871–882, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607103</ArticleId>
            <ArticleId IdType="pubmed">22674006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsokos GC: Systemic lupus erythematosus.
N Engl J Med
365: 2110–2121, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22129255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodnow CC: Multistep pathogenesis of autoimmune disease.
Cell
130: 25–35, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17632054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saxena R, Mahajan T, Mohan C: Lupus nephritis: Current update.
Arthritis Res Ther
13: 240, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3308062</ArticleId>
            <ArticleId IdType="pubmed">22078716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Migliorini A, Anders HJ: A novel pathogenetic concept-antiviral immunity in lupus nephritis.
Nat Rev Nephrol
8: 183–189, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22249778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M: The role of defective clearance of apoptotic cells in systemic autoimmunity.
Nat Rev Rheumatol
6: 280–289, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20431553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.
Proc Natl Acad Sci U S A
107: 9813–9818, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2906830</ArticleId>
            <ArticleId IdType="pubmed">20439745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ: Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.
J Immunol
187: 538–552, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3119769</ArticleId>
            <ArticleId IdType="pubmed">21613614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V: Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus.
Sci Transl Med
3: 73ra20, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3143837</ArticleId>
            <ArticleId IdType="pubmed">21389264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M: Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus.
Sci Transl Med
3: 73ra19, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3399524</ArticleId>
            <ArticleId IdType="pubmed">21389263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosch X: Systemic lupus erythematosus and the neutrophil.
N Engl J Med
365: 758–760, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21864171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hof D, Raats JM, Pruijn GJ: Apoptotic modifications affect the autoreactivity of the U1 snRNP autoantigen.
Autoimmun Rev
4: 380–388, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16081029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huck S, Deveaud E, Namane A, Zouali M: Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis.
FASEB J
13: 1415–1422, 1999</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10428765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karikó K, Ni H, Capodici J, Lamphier M, Weissman D: mRNA is an endogenous ligand for Toll-like receptor 3.
J Biol Chem
279: 12542–12550, 2004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14729660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A: U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7.
Blood
107: 3229–3234, 2006</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16368889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ, Krug A: Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis.
Arthritis Rheum
58: 1107–1115, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18383384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A: RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement.
J Exp Med
202: 1171–1177, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213226</ArticleId>
            <ArticleId IdType="pubmed">16260486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ: Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens.
J Exp Med
205: 1879–1888, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2525585</ArticleId>
            <ArticleId IdType="pubmed">18644972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lech M, Skuginna V, Kulkarni OP, Gong J, Wei T, Stark RW, Garlanda C, Mantovani A, Anders HJ: Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis.
J Pathol
220: 596–607, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20112371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.
Nature
416: 603–607, 2002</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11948342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis V, Banchereau J, Coffman RL, Pascual V, Barrat FJ: TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.
Nature
465: 937–941, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964153</ArticleId>
            <ArticleId IdType="pubmed">20559388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patole PS, Zecher D, Pawar RD, Gröne HJ, Schlöndorff D, Anders HJ: G-rich DNA suppresses systemic lupus.
J Am Soc Nephrol
16: 3273–3280, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16176997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ: Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus.
J Am Soc Nephrol
18: 1721–1731, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17460144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ: Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage.
Immunity
33: 967–978, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3010763</ArticleId>
            <ArticleId IdType="pubmed">21167752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha/beta) in immunity and autoimmunity.
Annu Rev Immunol
23: 307–336, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15771573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus.
J Exp Med
189: 1639–1648, 1999</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2193634</ArticleId>
            <ArticleId IdType="pubmed">10330443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zikherman J, Parameswaran R, Weiss A: Endogenous antigen tunes the responsiveness of naive B cells but not T cells.
Nature
489: 160–164, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3438375</ArticleId>
            <ArticleId IdType="pubmed">22902503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allam R, Sayyed SG, Kulkarni O, Lichtnekert J, Anders HJ: Murine double minute-2 drives systemic lupus erythematosus and lupus nephritis.
J Am Soc Nephrol
22: 2016–2027, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3279995</ArticleId>
            <ArticleId IdType="pubmed">21949095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Davidson A: BAFF and selection of autoreactive B cells.
Trends Immunol
32: 388–394, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3151317</ArticleId>
            <ArticleId IdType="pubmed">21752714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gayed M, Gordon C: Novel treatments for systemic lupus erythematosus.
Curr Opin Investig Drugs
11: 1256–1264, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21157645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lech M, Weidenbusch M, Kulkarni OP, Ryu M, Darisipudi MN, Susanti HE, Mittruecker HW, Mak TW, Anders HJ: IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production.
J Am Soc Nephrol
22: 1443–1452, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3148699</ArticleId>
            <ArticleId IdType="pubmed">21742731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caricchio R, McPhie L, Cohen PL: Ultraviolet B radiation-induced cell death: Critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution.
J Immunol
171: 5778–5786, 2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14634086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B: Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity.
J Immunol
140: 2197–2200, 1988</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3258330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis.
Arthritis Rheum
33: 1665–1673, 1990</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2242063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes GC: Progesterone and autoimmune disease.
Autoimmun Rev
11: A502–A514, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3431799</ArticleId>
            <ArticleId IdType="pubmed">22193289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tojo T, Friou GJ: Lupus nephritis: Varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei.
Science
161: 904–906, 1968</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4174454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob N, Stohl W: Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: Past, present, and future.
Autoimmunity
43: 84–97, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2809122</ArticleId>
            <ArticleId IdType="pubmed">20014977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, Qu Z, Chen MH, Gao JJ, Li ZY, Zheng X, Ao J, Zhu SN, Wang SX, Zhao MH, Zou WZ, Liu G: Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.
Kidney Int
77: 820–829, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20182417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M, International Society of Nephrology Working Group on the Classification of Lupus Nephritis. Renal Pathology Society Working Group on the Classification of Lupus Nephritis : The classification of glomerulonephritis in systemic lupus erythematosus revisited.
Kidney Int
65: 521–530, 2004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14717922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowling TK, Gilkeson GS: Mechanisms of tissue injury in lupus nephritis.
Arthritis Res Ther
13: 250, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3334648</ArticleId>
            <ArticleId IdType="pubmed">22192660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Chan TM: Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: Getting to know the unknown.
Clin Dev Immunol
2012: 139365, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3386553</ArticleId>
            <ArticleId IdType="pubmed">22761629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortensen ES, Rekvig OP: Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes.
J Am Soc Nephrol
20: 696–704, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19329762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedberg A, Fismen S, Fenton KA, Fenton C, Osterud B, Mortensen ES, Rekvig OP: Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes.
Arthritis Rheum
63: 1065–1075, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21190297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yung S, Cheung KF, Zhang Q, Chan TM: Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis.
J Am Soc Nephrol
21: 1912–1927, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3014006</ArticleId>
            <ArticleId IdType="pubmed">20847146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Z, Deocharan B, Scherer PE, Ozelius LJ, Putterman C: Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: The role of alpha-actinin.
J Immunol
176: 7704–7714, 2006</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16751418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA: Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens.
Autoimmunity
44: 373–383, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21244336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fenton KA, Tømmerås B, Marion TN, Rekvig OP: Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice.
Autoimmunity
43: 179–188, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19835488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekine H, Ruiz P, Gilkeson GS, Tomlinson S: The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition.
Mol Immunol
49: 317–323, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22000720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S: The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Arthritis Rheum
63: 1076–1085, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3079315</ArticleId>
            <ArticleId IdType="pubmed">21452327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao L, Haas M, Quigg RJ: Complement factor H deficiency accelerates development of lupus nephritis.
J Am Soc Nephrol
22: 285–295, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3029901</ArticleId>
            <ArticleId IdType="pubmed">21148254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niederer HA, Clatworthy MR, Willcocks LC, Smith KG: FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus.
Ann N Y Acad Sci
1183: 69–88, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20146709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allam R, Lichtnekert J, Moll A, Taubitz A, Vielhauer V, Anders HJ: Viral RNA and DNA trigger common antiviral responses in mesangial cells.
J Am Soc Nephrol
20: 1986–1996, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2736778</ArticleId>
            <ArticleId IdType="pubmed">19713315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fluer K, Allam R, Zecher D, Kulkarni O, Lichtnekert J, Schwarz M, Beutler B, Vielhauer V, Anders HJ: Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5: Implications for viral infection-associated glomerulonephritis.
Am J Pathol
175: 2014–2022, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774065</ArticleId>
            <ArticleId IdType="pubmed">19850889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hägele H, Allam R, Pawar RD, Anders HJ: Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1.
Nephrol Dial Transplant
24: 3312–3318, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19608629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hägele H, Allam R, Pawar RD, Reichel CA, Krombach F, Anders HJ: Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway.
Am J Pathol
175: 1896–1904, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774054</ArticleId>
            <ArticleId IdType="pubmed">19834059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C: Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis.
J Immunol
183: 6831–6838, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2876821</ArticleId>
            <ArticleId IdType="pubmed">19864599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ, Lichtnekert J, Allam R: Interferon-alpha and -beta in kidney inflammation.
Kidney Int
77: 848–854, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20237459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB: Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages.
Proc Natl Acad Sci U S A
107: 3012–3017, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840310</ArticleId>
            <ArticleId IdType="pubmed">20133703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Gröne HJ, Schlöndorff D: Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice.
FASEB J
18: 534–536, 2004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14734643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rich SA: Human lupus inclusions and interferon.
Science
213: 772–775, 1981</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6166984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allam R, Anders HJ: The role of innate immunity in autoimmune tissue injury.
Curr Opin Rheumatol
20: 538–544, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18698174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, Tsutsumi A, Hayashi T, Uchida K, Usui J, Yamagata K, Sumida T: Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis.
Clin Exp Immunol
159: 1–10, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2802690</ArticleId>
            <ArticleId IdType="pubmed">19807734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni O, Anders HJ: Chemokines in lupus nephritis.
Front Biosci
13: 3312–3320, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18508434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, Anders HJ: Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.
J Am Soc Nephrol
18: 2350–2358, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17625118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B: Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
J Am Soc Nephrol
16: 3592–3601, 2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16267157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D: Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
J Am Soc Nephrol
15: 1504–1513, 2004</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15153561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chong BF, Mohan C: Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.
Expert Opin Ther Targets
13: 1147–1153, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19670960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G: The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells.
J Immunol
170: 1466–1472, 2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12538709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, Cuccovillo I, Bastone A, Gobbi M, Valentino S, Doni A, Garlanda C, Danese S, Salvatori G, Sassano M, Evangelista V, Rossi B, Zenaro E, Constantin G, Laudanna C, Bottazzi B, Mantovani A: Regulation of leukocyte recruitment by the long pentraxin PTX3.
Nat Immunol
11: 328–334, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20208538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lech M, Römmele C, Kulkarni OP, Susanti HE, Migliorini A, Garlanda C, Mantovani A, Anders HJ: Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus.
PLoS ONE
6: e20118, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3103530</ArticleId>
            <ArticleId IdType="pubmed">21637713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM, Quigg RJ, Meffre E, Clark MR: In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.
J Immunol
186: 1849–1860, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3124090</ArticleId>
            <ArticleId IdType="pubmed">21187439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, Segerer S, Cohen CD: Intrarenal production of B-cell survival factors in human lupus nephritis.
Mod Pathol
24: 98–107, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20890272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espeli M, Bökers S, Giannico G, Dickinson HA, Bardsley V, Fogo AB, Smith KG: Local renal autoantibody production in lupus nephritis.
J Am Soc Nephrol
22: 296–305, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3029902</ArticleId>
            <ArticleId IdType="pubmed">21088295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH: Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.
Arthritis Rheum
62: 2443–2457, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920998</ArticleId>
            <ArticleId IdType="pubmed">20506300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A: Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice.
Arthritis Rheum
62: 1457–1468, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2917190</ArticleId>
            <ArticleId IdType="pubmed">20131293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apostolidis SA, Crispín JC, Tsokos GC: IL-17-producing T cells in lupus nephritis.
Lupus
20: 120–124, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21303828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A: A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis.
J Immunol
186: 4994–5003, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3159403</ArticleId>
            <ArticleId IdType="pubmed">21411733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsiari CG, Liossis SN, Sfikakis PP: The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: A reappraisal.
Semin Arthritis Rheum
39: 491–503, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19147182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smeets B, Kuppe C, Sicking EM, Fuss A, Jirak P, van Kuppevelt TH, Endlich K, Wetzels JF, Gröne HJ, Floege J, Moeller MJ: Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis.
J Am Soc Nephrol
22: 1262–1274, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137574</ArticleId>
            <ArticleId IdType="pubmed">21719782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smeets B, Angelotti ML, Rizzo P, Dijkman H, Lazzeri E, Mooren F, Ballerini L, Parente E, Sagrinati C, Mazzinghi B, Ronconi E, Becherucci F, Benigni A, Steenbergen E, Lasagni L, Remuzzi G, Wetzels J, Romagnani P: Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis.
J Am Soc Nephrol
20: 2593–2603, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2794226</ArticleId>
            <ArticleId IdType="pubmed">19875807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smeets B, Uhlig S, Fuss A, Mooren F, Wetzels JF, Floege J, Moeller MJ: Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells.
J Am Soc Nephrol
20: 2604–2615, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2794233</ArticleId>
            <ArticleId IdType="pubmed">19917779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryu M, Migliorini A, Miosge N, Gross O, Shankland S, Brinkkoetter PT, Hagmann H, Romagnani P, Liapis H, Anders HJ: Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury [published online ahead of print May 3, 2012].
J Pathol10.1002/path.4046</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22553158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croca SC, Rodrigues T, Isenberg DA: Assessment of a lupus nephritis cohort over a 30-year period.
Rheumatology (Oxford)
50: 1424–1430, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21415024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houssiau F: Thirty years of cyclophosphamide: Assessing the evidence.
Lupus
16: 212–216, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17432109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.
Ann Rheum Dis
69: 61–64, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19155235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ: 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
Am J Pathol
176: 2840–2847, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2877845</ArticleId>
            <ArticleId IdType="pubmed">20413687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ, China Leflunomide Lupus Nephritis Study Group : Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-centre observational study.
Lupus
17: 638–644, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18625636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan OT, Madaio MP, Shlomchik MJ: The central and multiple roles of B cells in lupus pathogenesis.
Immunol Rev
169: 107–121, 1999</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10450512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregersen JW, Jayne DR: B-cell depletion in the treatment of lupus nephritis.
Nat Rev Nephrol
8: 505–514, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22801948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group : Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study.
Arthritis Rheum
64: 1215–1226, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22231479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Arthritis Rheum
62: 222–233, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4548300</ArticleId>
            <ArticleId IdType="pubmed">20039413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weidenbusch M, Römmele C, Schröttle A, Anders HJ: Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.
Nephrol Dial Transplant
28: 106–111, 2013</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22764193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group : Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial.
Lancet
377: 721–731, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21296403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, BLISS-52 and BLISS-76 Study Groups : Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials.
Ann Rheum Dis
71: 1833–1838, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3465857</ArticleId>
            <ArticleId IdType="pubmed">22550315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mok CC: Abatacept for systemic lupus erythematosus: The outlook.
Expert Opin Biol Ther
12: 1559–1561, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22946545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P: The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum
62: 3077–3087, 2010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20533545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A: Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
Nat Rev Rheumatol
7: 170–178, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21283146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH: Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
Arthritis Rheum
64: 493–503, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4584406</ArticleId>
            <ArticleId IdType="pubmed">21905015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Nat Med
14: 748–755, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18542049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders HJ: Pseudoviral immunity - a novel concept for lupus.
Trends Mol Med
15: 553–561, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19896418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrat FJ, Coffman RL: Development of TLR inhibitors for the treatment of autoimmune diseases.
Immunol Rev
223: 271–283, 2008</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18613842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM, American College of Rheumatology : American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.
Arthritis Care Res (Hoboken)
64: 797–808, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3437757</ArticleId>
            <ArticleId IdType="pubmed">22556106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clowse ME, Magder L, Witter F, Petri M: Hydroxychloroquine in lupus pregnancy.
Arthritis Rheum
54: 3640–3647, 2006</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17075810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pons-Estel GJ, Alarcón GS, McGwin G, Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM, Lumina Study Group : Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.
Arthritis Rheum
61: 830–839, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2898742</ArticleId>
            <ArticleId IdType="pubmed">19479701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL: Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.
Eur J Immunol
37: 3582–3586, 2007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18034431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B, Lupus Interferon Skin Activity (LISA) Study Investigators : Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study.
Ann Rheum Dis
70: 1905–1913, 2011</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21798883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM, Kötter I, Lakomek HJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T: Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland—a consensus report.
Lupus
21: 386–401, 2012</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22072024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ: Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
J Pharmacol Exp Ther
328: 371–377, 2009</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18997060</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
